1. Home
  2. SNY
  3. SNY News

Latest Sanofi ADS (SNY) News on July 7, 2025

FDA Grants Orphan Drug Designation To Sanofi’s (SNY) Riliprubart
SNY

Insider Monkey

a day ago

FDA Grants Orphan Drug Designation To Sanofi’s (SNY) Riliprubart

Sanofi’s (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan
SNY

Insider Monkey

a day ago

Sanofi’s (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan

How Much of Your Portfolio Should Be in International Stocks?
SNY

The Wall Street Journal

3 days ago

How Much of Your Portfolio Should Be in International Stocks?

Mercedes to LVMH Are Blunting the EU’s Fight Against Trump’s Tariffs
SNY

Bloomberg

4 days ago

Mercedes to LVMH Are Blunting the EU’s Fight Against Trump’s Tariffs

Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA
SNY

Insider Monkey

4 days ago

Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA

SNY

Morningstar Research

5 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

10 European Dividend Stocks That Could Beat Their U.S. Counterparts
SNY

Barrons.com

6 days ago

10 European Dividend Stocks That Could Beat Their U.S. Counterparts

Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP
SNY

Pharmaceutical Technology

6 days ago

Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP

SNY

MT Newswires

6 days ago

Sector Update: Health Care Stocks Lean Lower Premarket Tuesday

Adagene announces up to $25 million strategic investment from Sanofi
SNY

GlobeNewswire

6 days ago

Adagene announces up to $25 million strategic investment from Sanofi

Sanofi (ENXTPA:SAN) Gains Orphan Drug Status In Japan For CIDP Treatment
SNY

Simply Wall St.

7 days ago

Sanofi (ENXTPA:SAN) Gains Orphan Drug Status In Japan For CIDP Treatment

Hedge Fund Strategy Built on Catastrophes Taps Hot New Trend
SNY

Bloomberg

7 days ago

Hedge Fund Strategy Built on Catastrophes Taps Hot New Trend

SNY

Argus Research

7 days ago

Analyst Report: Regeneron Phars, Inc

ESTEVE to acquire medicine to treat medullary thyroid cancer
SNY

PR Newswire

7 days ago

ESTEVE to acquire medicine to treat medullary thyroid cancer

Press release: Availability of the Q2 2025 Aide mémoire
SNY

GlobeNewswire

7 days ago

Press release: Availability of the Q2 2025 Aide mémoire

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
SNY

GlobeNewswire

7 days ago

Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee
SNY

Barrons.com

11 days ago

The Anti-Vax Movement Solidifies Control of the CDC’s Vaccine Committee

Kymera weakness a buying opportunity, says Stifel
SNY

TipRanks

11 days ago

Kymera weakness a buying opportunity, says Stifel

Morning Movers: General Mills dips following fourth quarter report
SNY

TipRanks

11 days ago

Morning Movers: General Mills dips following fourth quarter report

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
SNY

Zacks

11 days ago

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
SNY

PR Newswire

11 days ago

Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts

Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag
SNY

Zacks

12 days ago

Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi
SNY

BioPharma Dive

12 days ago

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

SNY

MT Newswires

12 days ago

Kymera Announces Sanofi to Advance KT-485 Into Clinical Testing

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
SNY

GlobeNewswire

12 days ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption
SNY

GlobeNewswire

12 days ago

United States Insulin Pens Market Research Report 2025-2033, Advances in Technology, Favorable Reimbursement Policies, Increasing Awareness and Adoption

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
SNY

GlobeNewswire

12 days ago

Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation

Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
SNY

Zacks

13 days ago

Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?

Allergic Rhinitis Market Report 2025-2035 | Innovative Drug Classes and Regional Trends Propel Expansion
SNY

GlobeNewswire

13 days ago

Allergic Rhinitis Market Report 2025-2035 | Innovative Drug Classes and Regional Trends Propel Expansion

SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma
SNY

Zacks

14 days ago

SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
SNY

GlobeNewswire

14 days ago

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

Sanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin Disease
SNY

Simply Wall St.

16 days ago

Sanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin Disease

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
SNY

Zacks

17 days ago

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

SNY

MT Newswires

17 days ago

Sector Update: Health Care Stocks Rise Premarket Friday

SNY

MT Newswires

17 days ago

Sector Update: Health Care

DoH – Abu Dhabi and Sanofi link for vaccine development
SNY

Pharmaceutical Technology

17 days ago

DoH – Abu Dhabi and Sanofi link for vaccine development

SNY

MT Newswires

17 days ago

Regeneron, Sanofi Say US FDA Approves Dupixent for Rare Skin Condition Disease

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
SNY

GlobeNewswire

17 days ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Trump administration weighs crackdown on pharma ads, Bloomberg says
SNY

TipRanks

19 days ago

Trump administration weighs crackdown on pharma ads, Bloomberg says

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
SNY

Zacks

20 days ago

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

SNY

MT Newswires

20 days ago

Market Chatter: Trump Administration to Consider Pharma Advertising Crackdown

SNY

GlobeNewswire

20 days ago

Press release: Sanofi successfully prices €1.5 billion bond issue

SNY

MT Newswires

21 days ago

European Equities Close Mostly Higher in Monday Trading; Renault CEO to Step Down, Expected to Join Kering

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
SNY

Zacks

21 days ago

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

SNY

MT Newswires

21 days ago

Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
SNY

GlobeNewswire

22 days ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
SNY

GlobeNewswire

22 days ago

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target
SNY

Insider Monkey

22 days ago

Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a €118 Price Target

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
SNY

Insider Monkey

22 days ago

Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis

Senators to propose ban on drug ads to consumers, WSJ reports
SNY

TipRanks

24 days ago

Senators to propose ban on drug ads to consumers, WSJ reports

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
SNY

Zacks

25 days ago

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
SNY

TipRanks

a month ago

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand
SNY

Simply Wall St.

a month ago

Sanofi (ENXTPA:SAN) Expands Beyfortus RSV Protection Production For Global Demand

Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
SNY

Zacks

a month ago

Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants

Sanofi: Information concerning the total number of voting rights and shares - May 2025
SNY

GlobeNewswire

a month ago

Sanofi: Information concerning the total number of voting rights and shares - May 2025

Merck antibody drug for RSV approved by FDA
SNY

BioPharma Dive

a month ago

Merck antibody drug for RSV approved by FDA

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
SNY

Benzinga

a month ago

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

Regeneron and Sanofi’s dupilumab shows promise in AD trial
SNY

Clinical Trials Arena

a month ago

Regeneron and Sanofi’s dupilumab shows promise in AD trial

Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care
SNY

CNW Group

a month ago

Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

SNY

MT Newswires

a month ago

Regeneron, Sanofi Say Atopic Dermatitis Trial Shows Improvement in Disease Severity

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
SNY

GlobeNewswire

a month ago

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Challenges pharma companies face in push into US manufacturing
SNY

Yahoo Finance Video

a month ago

Challenges pharma companies face in push into US manufacturing

Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
SNY

Insider Monkey

a month ago

Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success

SNY

GlobeNewswire

a month ago

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
SNY

Zacks

a month ago

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout

SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
SNY

Zacks

a month ago

SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease

Sanofi announces new data from two clinical studies on Sarclisa
SNY

TipRanks

a month ago

Sanofi announces new data from two clinical studies on Sarclisa

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
SNY

GlobeNewswire

a month ago

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
SNY

Insider Monkey

a month ago

Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
SNY

GlobeNewswire

a month ago

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

SNY

Morningstar Research

a month ago

Analyst Report: Sanofi

SNY

MT Newswires

a month ago

Sector Update: Health Care Stocks Retreat in Afternoon Trading

SNY

MT Newswires

a month ago

Sector Update: Health Care

Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of
SNY

GuruFocus.com

a month ago

Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
SNY

Zacks

a month ago

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
SNY

Investopedia

a month ago

Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover

SNY

MT Newswires

a month ago

Sector Update: Health Care

Stocks to Watch Monday: Alphabet, Tesla, UnitedHealth, Steel Dynamics
SNY

The Wall Street Journal

a month ago

Stocks to Watch Monday: Alphabet, Tesla, UnitedHealth, Steel Dynamics

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
SNY

Benzinga

a month ago

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

5 Things to Know Before the Stock Market Opens
SNY

Investopedia

a month ago

5 Things to Know Before the Stock Market Opens

SNY

MT Newswires

a month ago

Berenberg Trims Price Target on Sanofi to EUR118 From EUR120, Keeps Buy Rating

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
SNY

Barrons.com

a month ago

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

SNY

Pharmaceutical Technology

a month ago

Sanofi and Regeneron report results from two Phase III trials of COPD treatment

Sanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD Trial
SNY

Simply Wall St.

a month ago

Sanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD Trial

SNY

Morningstar Research

a month ago

Analyst Report: Sanofi

Regeneron stock sinks over trial data for smoker's lungs drug
SNY

Yahoo Finance Video

a month ago

Regeneron stock sinks over trial data for smoker's lungs drug

SNY

MT Newswires

a month ago

Top Midday Decliners

SNY

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More
SNY

Investopedia

a month ago

Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More

COPD Drug Developed by Regeneron, Sanofi Fails Key Test
SNY

Investopedia

a month ago

COPD Drug Developed by Regeneron, Sanofi Fails Key Test

Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies
SNY

Zacks

a month ago

Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies

Regeneron Stock Plunges. Why a Drug Trial Missed the Mark.
SNY

Barrons.com

a month ago

Regeneron Stock Plunges. Why a Drug Trial Missed the Mark.

SNY

MT Newswires

a month ago

Sector Update: Health Care Stocks Fall Pre-Bell Friday

Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
SNY

Investor's Business Daily

a month ago

Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure

SNY

MT Newswires

a month ago

Sector Update: Health Care

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
SNY

Benzinga

a month ago

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data

Stocks to Watch Friday: Dell, Costco, Ulta, Regeneron
SNY

The Wall Street Journal

a month ago

Stocks to Watch Friday: Dell, Costco, Ulta, Regeneron

SNY

MT Newswires

a month ago

Update: Sanofi, Regeneron Pharmaceuticals Report Mixed Results From 2 Phase 3 Trials of Itepekimab

Regeneron shares slide on mixed trial data for smoker's lung drug
SNY

Reuters

a month ago

Regeneron shares slide on mixed trial data for smoker's lung drug

Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials
SNY

The Wall Street Journal

a month ago

Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials

Share on Social Networks: